Business Description
Arrowhead Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US04280A1007
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.86 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 0.74 | |||||
Debt-to-EBITDA | -0.44 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 0.18 | |||||
Beneish M-Score | -4.9 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 37.2 | |||||
3-Year EBITDA Growth Rate | -23.9 | |||||
3-Year EPS without NRI Growth Rate | -31.7 | |||||
3-Year FCF Growth Rate | -42.5 | |||||
3-Year Book Growth Rate | -17.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 5.18 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
14-Day RSI | 2.44 | |||||
12-1 Month Momentum % | -58.11 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.73 | |||||
Quick Ratio | 3.73 | |||||
Cash Ratio | 3.46 | |||||
Days Sales Outstanding | 56.06 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.6 | |||||
Shareholder Yield % | -1.17 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -164.75 | |||||
Net Margin % | -163.32 | |||||
FCF Margin % | -212.2 | |||||
ROE % | -91.59 | |||||
ROA % | -37.38 | |||||
ROIC % | -81.36 | |||||
ROC (Joel Greenblatt) % | -100.15 | |||||
ROCE % | -40.11 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 13.11 | |||||
PB Ratio | 14.8 | |||||
Price-to-Tangible-Book | 15.77 | |||||
EV-to-EBIT | -9.35 | |||||
EV-to-Forward-EBIT | -5.85 | |||||
EV-to-EBITDA | -9.84 | |||||
EV-to-Forward-EBITDA | -6.52 | |||||
EV-to-Revenue | 14.53 | |||||
EV-to-Forward-Revenue | 15.15 | |||||
EV-to-FCF | -6.56 | |||||
Price-to-Median-PS-Value | 0.34 | |||||
Earnings Yield (Greenblatt) % | -10.7 | |||||
FCF Yield % | -14.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Arrowhead Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | 3,302.204 | ||
EPS (TTM) (MXN) | -47.248 | ||
Beta | -0.05 | ||
Volatility % | 55.5 | ||
14-Day RSI | 2.44 | ||
14-Day ATR (MXN) | 0.000007 | ||
20-Day SMA (MXN) | 586 | ||
12-1 Month Momentum % | -58.11 | ||
52-Week Range (MXN) | 583 - 1399 | ||
Shares Outstanding (Mil) | 124.2 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Arrowhead Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Arrowhead Pharmaceuticals Inc Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
Arrowhead Pharmaceuticals Inc Frequently Asked Questions
What is Arrowhead Pharmaceuticals Inc(MEX:ARWR)'s stock price today?
When is next earnings date of Arrowhead Pharmaceuticals Inc(MEX:ARWR)?
Does Arrowhead Pharmaceuticals Inc(MEX:ARWR) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |